PDF(Pubmed)
Abstract：
BACKGROUND: Real-world data regarding patient characteristics, adjuvant treatment patterns, and long-term survival outcomes are needed to better understand unmet needs among patients with completely resected early-stage non-small cell lung cancer (NSCLC).
METHODS: Electronic medical records from the U.S.-based ConcertAI Patient360™ database were analyzed in patients with stage IB-IIIA NSCLC who underwent complete resection prior to March 1, 2016. Patients were followed until death or July 1, 2021. This study evaluated adjuvant chemotherapy use, and overall survival (OS) and real-world disease-free survival (rwDFS) outcomes using the Kaplan-Meier method. The correlation between OS and rwDFS was assessed using the Kendall rank test. Among patients who did not recur 5 years following surgery, landmark analyses of OS and rwDFS were conducted to understand the subsequent survival impact of remaining disease-free for at least 5 years.
RESULTS: Data from 441 patients with completely resected stage IB-IIIA NSCLC were included. About 35% of patients received adjuvant chemotherapy post-resection. Median OS and rwDFS from resection were 83.1 months and 42.4 months, respectively. The 5-year OS and rwDFS rates were 65.7% and 42.1%, respectively. OS and rwDFS were positively correlated (Kendall rank correlation coefficient = 0.67; p < 0.0001). Among patients without recurrence within 5 years after resection, the subsequent 5-year OS and rwDFS survival rates were 52.9% and 36.6%, respectively.
CONCLUSIONS: Use of adjuvant chemotherapy was low, and the overall 5-year OS rate remained low despite all patients having undergone complete resection. Patients who remained non-recurrent over time had favorable subsequent long-term survival.
METHODS: Electronic medical records from the U.S.-based ConcertAI Patient360™ database were analyzed in patients with stage IB-IIIA NSCLC who underwent complete resection prior to March 1, 2016. Patients were followed until death or July 1, 2021. This study evaluated adjuvant chemotherapy use, and overall survival (OS) and real-world disease-free survival (rwDFS) outcomes using the Kaplan-Meier method. The correlation between OS and rwDFS was assessed using the Kendall rank test. Among patients who did not recur 5 years following surgery, landmark analyses of OS and rwDFS were conducted to understand the subsequent survival impact of remaining disease-free for at least 5 years.
RESULTS: Data from 441 patients with completely resected stage IB-IIIA NSCLC were included. About 35% of patients received adjuvant chemotherapy post-resection. Median OS and rwDFS from resection were 83.1 months and 42.4 months, respectively. The 5-year OS and rwDFS rates were 65.7% and 42.1%, respectively. OS and rwDFS were positively correlated (Kendall rank correlation coefficient = 0.67; p < 0.0001). Among patients without recurrence within 5 years after resection, the subsequent 5-year OS and rwDFS survival rates were 52.9% and 36.6%, respectively.
CONCLUSIONS: Use of adjuvant chemotherapy was low, and the overall 5-year OS rate remained low despite all patients having undergone complete resection. Patients who remained non-recurrent over time had favorable subsequent long-term survival.
摘要：
背景：关于患者特征的真实世界数据，辅助治疗模式，和长期生存结局需要更好地了解完全切除的早期非小细胞肺癌(NSCLC)患者的未满足需求.
方法：在2016年3月1日之前接受完全切除的IB-IIIA期非小细胞肺癌患者中，分析了来自美国ConcertAIPatient360™数据库的电子病历。随访患者直至死亡或2021年7月1日。这项研究评估了辅助化疗的使用，使用Kaplan-Meier方法的总生存期（OS）和真实世界无病生存期（rwDFS）结局。使用Kendall秩检验评估OS和rwDFS之间的相关性。在手术后5年没有复发的患者中，对OS和rwDFS进行了具有里程碑意义的分析,以了解保持至少5年无病的后续生存影响.
结果：纳入了441例完全切除的IB-IIIA期非小细胞肺癌患者的数据。约35%的患者在切除后接受辅助化疗。手术切除的中位OS和rwDFS分别为83.1个月和42.4个月，分别。5年OS和rwDFS率分别为65.7%和42.1%，分别。OS和rwDFS呈正相关(Kendall秩相关系数=0.67;p<0.0001)。在切除后5年内无复发的患者中，随后的5年OS和rwDFS生存率分别为52.9%和36.6%，分别。
结论：辅助化疗的使用率较低，尽管所有患者都接受了完全切除,但5年总OS率仍然很低.随着时间的推移保持非复发的患者具有良好的后续长期生存率。
方法：在2016年3月1日之前接受完全切除的IB-IIIA期非小细胞肺癌患者中，分析了来自美国ConcertAIPatient360™数据库的电子病历。随访患者直至死亡或2021年7月1日。这项研究评估了辅助化疗的使用，使用Kaplan-Meier方法的总生存期（OS）和真实世界无病生存期（rwDFS）结局。使用Kendall秩检验评估OS和rwDFS之间的相关性。在手术后5年没有复发的患者中，对OS和rwDFS进行了具有里程碑意义的分析,以了解保持至少5年无病的后续生存影响.
结果：纳入了441例完全切除的IB-IIIA期非小细胞肺癌患者的数据。约35%的患者在切除后接受辅助化疗。手术切除的中位OS和rwDFS分别为83.1个月和42.4个月，分别。5年OS和rwDFS率分别为65.7%和42.1%，分别。OS和rwDFS呈正相关(Kendall秩相关系数=0.67;p<0.0001)。在切除后5年内无复发的患者中，随后的5年OS和rwDFS生存率分别为52.9%和36.6%，分别。
结论：辅助化疗的使用率较低，尽管所有患者都接受了完全切除,但5年总OS率仍然很低.随着时间的推移保持非复发的患者具有良好的后续长期生存率。
